RA
ASBP

Resolute Advisors’s Aspire Biopharma ASBP Stock Holding History

Resolute Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130
Closed -$20.6K – 98
2025
Q4 		$20.6K Buy
130
+61
+88% +$15.3K 0.01% 73
2025
Q3 		$17.1K Buy
+69
New +$34.5K ﹤0.01% 74

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Resolute Advisors's ASBP Position: Q1 2026 in Review

Resolute Advisors sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 130 shares — an estimated $20.6K sold.

Resolute Advisors first reported a position in ASBP in Q3 2025 and held it in 2 quarters. The position peaked at $20.6K in Q4 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Resolute Advisors reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
  • Resolute Advisors sold 130 Aspire Biopharma shares in Q1 2026, an estimated $20.6K.
  • Resolute Advisors first reported a position in Aspire Biopharma in Q3 2025 and held it in 2 quarters.
  • Resolute Advisors's Aspire Biopharma position peaked at $20.6K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Resolute Advisors's 13F filing for Q1 2026, filed 7 May 2026.